Physician profile
Cesci Wright
NPI 1174161962
$2,928.09
in general payments reported to CMS, 2019-2025
19 companies · $723 in 2025
The $723 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $421 · 2022: $607 · 2023: $496 · 2024: $681 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888 · Education: $12.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,887.64 |
| Education | $12.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $441.35 | 2022-2025 | Zerbaxa, Dificid, Recarbrio |
| Theratechnologies INC. | $435.83 | 2022-2025 | Trogarzo, Egrifta |
| Shionogi INC | $305.13 | 2022-2025 | Fetroja |
| Insmed, INC. | $279.97 | 2022-2025 | Arikayce |
| Paratek Pharmaceuticals, INC. | $219.37 | 2022-2025 | Nuzyra |
| Gilead Sciences, INC. | $219.13 | 2022-2025 | Veklury, Biktarvy |
| Abbvie INC. | $213.65 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.06 | 2021 | |
| Janssen Biotech, INC. | $138.23 | 2022-2023 | Symtuza |
| Novo Nordisk INC | $125.00 | 2021 | |
| Xeris Pharmaceuticals, INC. | $124.95 | 2021 | |
| La Jolla Pharmaceutical Company | $116.56 | 2023-2024 | Xerava, Xacduro |
| Melinta Therapeutics, LLC | $63.41 | 2022-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Global Blood Therapeutics, INC. | $24.70 | 2022 | |
| Viiv Healthcare Company | $19.57 | 2025 | Dovato |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $15.93 | 2021 | |
| Aimmune Therapeutics, INC. | $15.82 | 2025 | Vowst |
| Takeda Pharmaceuticals U.S.A., INC. | $14.68 | 2025 | Cuvitru |
| Bayer Healthcare Pharmaceuticals INC. | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesci Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.